ANACARDIO
AnaCardio is a clinical stage biopharmaceutical company developing novel drugs to treat heart failure.
ANACARDIO
Social Links:
Industry:
Biopharma Biotechnology Medical
Founded:
2017-01-01
Address:
Solna, Stockholms Lan, Sweden
Country:
Sweden
Website Url:
http://www.anacardio.com
Total Employee:
1+
Status:
Active
Total Funding:
183 M SEK
Technology used in webpage:
ReCAPTCHA Person Schema Swedish Server Location
Similar Organizations
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Eden Biologics
Eden Biologics is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Prolocor
Prolocor is a biotechnology company that develops diagnostic tests for cardiovascular diseases.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Urovant Sciences
Urovant Sciences is a global biopharmaceutical company focused on developing novel therapies for urologic conditions.
Vivodyne
Vivodyne develops an automated robotic system that discovers life-changing drugs and cellular therapies.
Current Advisors List
Investors List
Flerie Invest
Flerie Invest investment in Series A - AnaCardio
Industrifonden
Industrifonden investment in Series A - AnaCardio
3B Ventures
3B Ventures investment in Series A - AnaCardio
AnnHelene Ljungström
AnnHelene Ljungström investment in Debt Financing - AnaCardio
Fredrik Ljungström
Fredrik Ljungström investment in Debt Financing - AnaCardio
Karolinska
Karolinska investment in Debt Financing - AnaCardio
Nybohov Invest
Nybohov Invest investment in Debt Financing - AnaCardio
Karolinska
Karolinska investment in Seed Round - AnaCardio
Official Site Inspections
http://www.anacardio.com Semrush global rank: 13.32 M Semrush visits lastest month: 78
- Host name: webfront1.webcluster.loopia.se
- IP address: 93.188.2.51
- Location: Sweden
- Latitude: 59.3247
- Longitude: 18.056
- Timezone: Europe/Stockholm
More informations about "AnaCardio"
About us - AnaCardio
AnaCardio was founded based on ground-breaking research from Karolinska Institutet showing improved contractility of the heart muscle through a unique and differentiated mechanism. ...See details»
AnaCardio strengthens its organization - AnaCardio
Sep 19, 2022 Stockholm Sweden – October 25, 2021 Karolinska Development’s portfolio company AnaCardio strengthens its organization to facilitate clinical trial of the drug candidate …See details»
Org Chart AnaCardio - The Official Board
Organizational Chart of AnaCardio. AnaCardio www.anacardio.com. has 14 executives +46 2112 8222; Add an executive. AnaCardio (KDEVF) News . Anything missing? We search for you. …See details»
AnaCardio - Crunchbase Company Profile & Funding
Organization. AnaCardio . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. AnaCardio …See details»
AnaCardio Company Profile: Overview and Full News Analysis
AnaCardio aims to address this unmet need by developing novel inotropic agents that enhance contractility without the adverse effects commonly associated with existing therapies. The …See details»
Karolinska Development’s portfolio company AnaCardio …
STOCKHOLM SWEDEN – October 25, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the portfolio company AnaCardio has strengthened its …See details»
AnaCardio Company Profile 2024: Valuation, Funding …
AnaCardio General Information Description. Developer of therapeutic drugs designed to improve clinical outcomes in cardiac failure. The company's drugs improve the contractility of the heart muscle through a differentiated …See details»
AnaCardio AB - Drug pipelines, Patents, Clinical trials - Synapse
Clinical Trials associated with AnaCardio AB. CTIS2022-500347-20-00 / Recruiting - AC01-01. Start Date 23 Feb 2023. ... The statistics for drugs in the Pipeline is the current organization …See details»
AnaCardio – 20 Years of Innovation
Mar 5, 2024 PHARMA Based on research at Karolinska Institutet, AnaCardio is developing a completely new drug concept for chronic heart failure. This enterprising company has received …See details»
Anacardio - Products, Competitors, Financials, Employees, …
AnaCardio successfully completes first part of AC01 HFrEF study and provides a clinical update. Sep 17, 2024. AnaCardio Tue, Sep 17, 2024 08:30 CET Stockholm, Sweden, September 17, …See details»
News - AnaCardio
Sep 17, 2024 AnaCardio, a Swedish clinical-stage biopharmaceutical company focusing on developing novel. ... AnaCardio strengthens its organization Stockholm Sweden – October 25, …See details»
AnaCardio | Helsinn
Feb 3, 2022 Lugano, Switzerland and Stockholm, Sweden, February 3, 2022 – Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of …See details»
AnaCardio - Funding, Financials, Valuation & Investors - Crunchbase
AnaCardio is a clinical stage biopharmaceutical company developing novel drugs to treat heart failure. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. ... How much …See details»
AnaCardio, a Worldwide Sponsor, Receives Regulatory Approval to …
Nov 17, 2022 AnaCardio today announces approval for the GOAL-HF1 Phase 1b/2a study from the competent authorities and ethics committes in Sweden, The Netherlands, Italy and the …See details»
AnaCardio - Company Profile - Tracxn
Oct 22, 2024 AnaCardio ranks 7th among 40 active competitors. 15 of its competitors are funded while 4 have exited. Overall, AnaCardio and its competitors have raised over $1.13B in …See details»
AnaCardio - Overview, News & Similar companies | ZoomInfo.com
Jan 17, 2024 AnaCardio selected as finalist at the J.P. Morgan Asset Management: Life Sciences Innovation Summit PRESS RELEASE Stockholm, Sweden, April 4 , 2024 …See details»
AnaCardio appoints Patrik Strömberg as CEO
Sep 19, 2022 Stockholm, Sweden, 22 October 2021 AnaCardio appoints Patrik Strömberg as CEO.AnaCardio AB announces today that Patrik Strömberg has been appointed Chief …See details»
2023-24 Annual Report - American Heart Association
The American Heart Association’s ESG report details efforts to ensure our organization is a relevant, responsible, ethical and transparent force for the health of our communities and our …See details»
R&D - AnaCardio
AnaCardio has initiated a Phase 1b/2a study in HFrEF patients: AC01-01 Heart Failure Dose Escalation and 28 day Cohort Expansion Clinical Trial. It is a randomized, double-blind, …See details»
AnaCardio Receives Regulatory Approval to Start a Phase 1b/2a …
Stockholm, Sweden, November 17, 2022 AnaCardio today announces approval for the GOAL-HF1 Phase 1b/2a study from the competent authorities and ethics committes in Sweden, The …See details»